Cost-effectiveness analysis of seven treatments vs sorafenib as first-line therapy for advanced hepatocellular carcinoma in China

Table 1 Bayesian surface under the cumulative ranking curve and ranking profiles for efficacy endpoints (progression-free survival and overall survival)

Treatment	PFS			OS			Mean (PFS and OS)
	SUCRA (%)	Rank	PrBest (%)	SUCRA (%)	Rank	PrBest (%)	SUCRA (%)	Rank
Placebo	0	23	0	1	22.8	0	0.50	22.90
Sorafenib	28.2	16.8	0	28.5	16.7	0	28.35	16.75
Lenvatinib	75.5	6.4	0	43.5	13.4	0	59.50	9.90
Donafenib	38.4	14.6	0	59.1	10	0	48.75	12.30
Sintilimab plus IBI305	85.7	4.2	0	92.3	2.7	6.8	89.00	3.45
Rivoceranib plus camrelizumab	89.7	3.3	0.1	88.9	3.5	2.2	89.30	3.40
Tislelizumab	15.3	19.6	0	57.4	10.4	0	36.35	15.00
Avastin plus tecentriq	74	6.7	0	85.2	4.3	0.9	79.60	5.50
Cabozantinib plus atezolizumab	75.4	6.4	0	48.6	12.3	0	62.00	9.35
Single Tremelimumab Regular Interval Durvalumab	44.4	13.2	0	71	7.4	0	57.70	10.30
Durvalumab	25	17.5	0	55.5	10.8	0	40.25	14.15
Lenvatinib plus pembrolizumab	89.1	3.4	0	70.1	7.6	0	79.60	5.50
Lenvatinib plus TACE	100	1	99.9	99.4	1.1	89.9	99.70	1.05
Sorafenib plus TACE	63.4	9	0	45.6	13	0	54.50	11.00
Nivolumab	38.7	14.5	0	57.4	10.4	0	48.05	12.45
Sorafenib plus erlotinib	12.2	20.3	0	42.1	13.7	0	27.15	17.00
Linifanib	60.9	9.6	0	22.4	18.1	0	41.65	13.85
Sunitinib	12.1	20.3	0	4.9	21.9	0	8.50	21.10
Brivanib	26.8	17.1	0	19.2	18.8	0	23.00	17.95
Sorafenib plus pravastatin	28.5	16.7	0	31.3	16.1	0	29.90	16.40
Sorafenib plus doxorubicin	37.9	14.7	0	24.3	17.7	0	31.10	16.20
Sorafenib plus hepatic arterial infusion chemotherapy	60.2	9.8	0	31.4	16.1	0	45.80	12.95
Avastin plus toripalimab	68.6	7.9	0	70.9	7.4	0.1	69.75	7.65

OS: Overall survival; PFS: Progression-free survival; PrBest: Probability of being best; SUCRA: Surface under the cumulative ranking curve; TACE: Transarterial chemoembolization.